Safety and efficacy of Palbociclib in combination with endocrine therapy in ER-positive HER2-negative advanced breast cancer-multi-institutional retrospective study -KBCOG-14
Phase 2
Recruiting
- Conditions
- ER-positive HER2-negative advanced breast cancer
- Registration Number
- JPRN-UMIN000036224
- Lead Sponsor
- Kobe Breast Cancer Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 200
Inclusion Criteria
Not provided
Exclusion Criteria
treated by Palbociclib with endocrine therapy for less than 1 week
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method PFS OS Adverse events
- Secondary Outcome Measures
Name Time Method